Combined use of apatinib mesylate and vinorelbine versus vinorelbine alone in recurrent or metastatic triple-negative breast cancer: study protocol for a randomized controlled clinical trial

Shuo Wu(Hainan University), Tao Sun(Liaoning Cancer Hospital & Institute), Junnan Xu(Wenzhou Medical University), Cui Jiang(Liaoning Cancer Hospital & Institute), Huan Li(Liaoning Cancer Hospital & Institute), Liang Zhang(Liaoning Cancer Hospital & Institute)
Trials
May 24, 2020
10.1186/s13063-020-04342-x
Cited by 10

Related Papers

Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|724
Sirt3 modulate renal ischemia‐reperfusion injury through enhancing mitochondrial fusion and activating the ERK‐OPA1 signaling pathway
|Journal of Cellular Physiology|2019|115
Smartphone-assisted colorimetric sensor arrays based on nanozymes for high throughput identification of heavy metal ions in salmon
|Journal of Hazardous Materials|2024|55
A phase 3 study of rituximab biosimilar HLX01 in patients with diffuse large B-cell lymphoma
|Journal of Hematology & Oncology|2020|50
Perspectives for the Role of Single-Atom Nanozymes in Assisting Food Safety Inspection and Food Nutrition Evaluation
|Analytical Chemistry|2024|46